Últimas noticias sobre Aspira Womens Health (NASDAQ:AWH) Bolsa

Aspira Womens Health

Allied World Assurance

Allied World Assurance Company Holdings, AG

NYSE

Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.

Aspira Women's Health Inc. - Common Stock

Aspira Womens Health Inc

ANGO WORLD HOLDINGS INC by ANGO World Holdings, Inc.

Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) reported quarterly sales of $2.200 million which missed the analyst consensus estimate of $2.775 million by 20.72 percent. This is a 0.77 percent decrease over sales of $2.217 million the same period last year.

Earnings

Earnings Misses

News

Aspira Womens Health Q3 Sales $2.200M Miss $2.775M Estimate

AFMD

AGAE

AIRI

AKYA

AMAT

AQMS

AREC

ASND

ASTS

AZUL

BENF

BILI

BIOR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BKTI

BKYI

BLUE

BNAI

BNZI

BRAG

BTAI

CASI

CELC

CINT

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNVS

CRIS

CWCO

DARE

DBGI

DESP

DFLI

DLPN

DMRC

DNMR

DPRO

DTST

EAST

EFXT

ELUT

EWCZ

FLNT

FTLF

GAMB

GAME

GCTS

GDEV

GLOB

HYLN

IMCC

INKT

INTR

ITRM

IVVD

IZEA

LCTX

LIQT

LOCL

LUNR

MITQ

MOVE

MSGM

MUFG

NICE

NOMD

NTES

OCFT

OCUL

OKLO

ONEW

ORGN

PDSB

PHGE

POCI

POST

Earnings Scheduled For November 14, 2024

Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) is set to give its latest quarterly earnings report on Thursday, 2024-11-14. Here's what investors need to know before the announcement.
Analysts estimate that Aspira Womens Health will report an earnings per share (EPS) of $-0.24. 
Anticipation surrounds Aspira Womens Health's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Performance in Previous Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.02, leading to a 3.54% drop in the share price on the subsequent day.
Here's a look at Aspira Womens Health's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.30</td>
<td>-0.34</td>
<td>-0.45</td>
<td>-0.51</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.28</td>
<td>-0.39</td>
<td>-0.30</td>
<td>-0.48</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-5.0%</td>
<td>-10.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731510249_0.png" alt="eps graph" />
<h3>Aspira Womens Health Share Price Analysis</h3>
Shares of Aspira Womens Health were trading at $0.8382 as of November 12. Over the last 52-week period, shares are down 77.93%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/AWH/earnings">To track all earnings releases for Aspira Womens Health visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Aspira Womens Health

Aspira Women's Health Expands Its Co-Marketing And Distribution Collaboration With BioReference To Include OvaWatch

<h3>Gainers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 93.4% to $1.12 during Monday's pre-market session. The market value of their outstanding shares is at $6.3 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares rose 71.53% to $9.09. The market value of their outstanding shares is at $6.6 million. </li>
<li>Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) shares moved upwards by 32.1% to $6.46. The market value of their outstanding shares is at $396.4 million. </li>
<li>Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) shares moved upwards by 22.27% to $1.18. The company's market cap stands at $18.9 million. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) stock rose 21.04% to $5.69. The company's market cap stands at $592.6 million. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) stock moved upwards by 15.5% to $1.49. The market value of their outstanding shares is at $22.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Koninklijke Philips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) stock declined by 17.0% to $26.29 during Monday's pre-market session. The market value of their outstanding shares is at $24.5 billion. As per the news, the Q3 earnings report came out today. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) stock fell 12.88% to $14.75. The company's market cap stands at $51.9 million. </li>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) stock decreased by 10.84% to $0.36. The market value of their outstanding shares is at $19.8 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock declined by 9.84% to $0.32. The company's market cap stands at $4.7 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) shares declined by 8.88% to $1.54. The market value of their outstanding shares is at $109.8 million. </li>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) stock decreased by 8.06% to $0.44. The market value of their outstanding shares is at $14.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ACRS

ENSC

EVOK

GLUE

HCTI

MIRA

MNDR

MNPR

MRNS

RVNC

12 Health Care Stocks Moving In Monday's Pre-Market Session

Aspira Women's Health Inc. ("Aspira") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced it has been selected by the <a href="https://www.globenewswire.com/Tracker?data=ebGQ2qlJRrvsdoF8GsXnWS67fQx7x8qEuWQB8gLcrMJSG3PBxTDifvHi6676MBhQbI_MzxDi10G6UwX6-5O9AR5s67GVwVAif6-zmQge86zv64DWH-H1m7Z3m7WIUSrn">Advanced Research Projects Agency for Health</a> (ARPA-H) as an <a href="https://www.globenewswire.com/Tracker?data=7HLQutQNP4W-KDNFtzd3sXRc1I2g-4zOXAeMbaogQTXaTguCv6k0IO5gWaqofeEFpMQt3OqFkihWUaPqbYpyYH7Ee0ZqoEAwim2iB5RanbDchBBHqMeGK2wN_qPTzy1UCbH54o_vGvcdc8W9GFev1mwAPzs-6ty-aT0oH6hAyuzpuZHTlfAOocgPr3z1FHF_">awardee</a> of the <a href="https://www.globenewswire.com/Tracker?data=6rbzRQN8qF0aneVxY5NWZxfs9AyeTPBA8sX7upadhcXQnvWNEf83oPP0yF3ujMcbMlJ5frtxSNo32zVFYCi_1uUCBBP-QAEugo31ziCe8GLI2Y3583TEpvsa08W2Hqjz">Sprint for Women's Health</a> to address critical unmet challenges in women's health, champion transformative innovations, and tackle health conditions that uniquely or disproportionately affect women. Aspira will receive $10 million in funding over two years through the Sprint for Women's Health launchpad track for later-stage health solutions.
Funding from the project will support the continued development of Aspira's ground-breaking multi-marker blood test to aid in the detection of endometriosis, known by its working name EndoMDx. Aspira will receive milestone-based payments of up to $10 million over a 2-year period. Additionally, Aspira will work with an ARPA-H Program Manager and the ARPA-H Investor Catalyst Hub in the design, development and commercial launch of the non-invasive test to identify endometriosis. The award is intended to provide access to a team of world-class subject matter experts and advisors to help ensure the successful completion and commercial launch of the test before the end of the contract term.&nbsp;&nbsp;&nbsp;

Contracts

Aspira Women's Health Selected To Receive $10M Award Over A 2-Year Period From ARPA-H's Sprint For Women's Health To Address Critical Unmet Challenges In Women's Health, Champion Transformative Innovations, And Tackle Health Conditions That Uniquely Or Disproportionately Affect Women

Biotech

Government

Regulations

General

Aspira Women's Health OvaWatch Receives Approval From New York State Department Of Health

Aspira Women's Health Inc. ("Aspira") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the publication of a paper in the journal Gynecologic Oncology highlighting data demonstrating that a multimodal assay combining miRNA with protein biomarkers, age, and menopausal status offered the most accurate classification of patients with an adnexal mass for the identification of early-stage ovarian cancer.

Aspira Women's Health Announces Publication Of Data Demonstrating Performance Of Its In-Development Blood Test For The Assessment Of Malignancy Risk In Patients With An Adnexal Mass

Alliance Global Partners analyst Ben Haynor maintains Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) with a Buy and lowers the price target from $7 to $5.5.

Price Target

Analyst Ratings

Alliance Global Partners Maintains Buy on Aspira Womens Health, Lowers Price Target to $5.5

Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.30) by 6.67 percent. The company reported quarterly sales of $2.423 million which missed the analyst consensus estimate of $2.600 million by 6.81 percent. This is a 2.73 percent decrease over sales of $2.491 million the same period last year.

Earnings Beats

Aspira Womens Health Q2 2024 GAAP EPS $(0.28) Beats $(0.30) Estimate, Sales $2.423M Miss $2.600M Estimate

Offerings

Aspira Women's Health Inc Files For Offering Of Up To 2.5M Shares By The Selling Stockholders

WIIM

Aspira Women's Health shares are trading higher after the company announced that preliminary OvaWatch volume during Q2 2024 grew 24% quarter-over-quarter to 1,307 units.

Preliminary OvaWatch&#xAE; volume during Q2 2024 grew 24% over the prior quarter to 1,307 units &nbsp;
Preliminary OvaSuiteSM volume during Q2 2024 grew 11% over the prior quarter to 6,471 units
AUSTIN, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced preliminary second quarter 2024 OvaSuite product volume and highlights.
Preliminary Second Quarter 2024 Product Volume and Highlights
<ul>
<li>The number of OvaWatch tests performed during the second quarter ended June 30, 2024, was 1,307, an increase of 48%, compared to the 884 tests in the same period last year, and an increase of 24% to the 1,052 tests sequentially. &nbsp;</li>
<li>The number of OvaSuite tests performed during the second quarter ended June 30, 2024, was 6,471, an increase of 3% compared to the 6,289 tests in the same period last year, and an increase of 11% to the 5,829 tests in the first quarter. &nbsp;</li>
<li>The Company was notified that it has been selected as a finalist for an ARPA-H grant to support further development of its protein + microRNA blood test for endometriosis. Announcement of the final grant award recipients is anticipated in the second half of 2024. &nbsp;</li>
<li>The Company has completed a comprehensive analysis of its biobank and has identified up to 70,000 serum, plasma, and whole blood samples that are available for secondary research. The Company is exploring opportunities to create non-dilutive sources of cash through related collaborations.</li>
</ul>
 &nbsp;

Guidance

Aspira Women's Health Announces Preliminary OvaWatch Volume During Q2 2024 Grew 24% QoQ To 1,307 Units; Preliminary OvaSuite Volume During Q2 2024 Grew 11% QoQ To 6,471 Units

<h3>Gainers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock rose 109.5% to $2.64 during Thursday's pre-market session. The company's market cap stands at $2.2 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock moved upwards by 37.23% to $1.29. The company's market cap stands at $24.3 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares moved upwards by 21.37% to $1.59. The company's market cap stands at $1.5 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) stock increased by 13.63% to $2.5. The market value of their outstanding shares is at $1.4 million. </li>
<li>Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) stock increased by 13.46% to $3.37. The company's market cap stands at $381.0 million. </li>
<li>Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) stock increased by 12.32% to $0.41. The market value of their outstanding shares is at $10.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) stock declined by 15.5% to $1.01 during Thursday's pre-market session. The market value of their outstanding shares is at $25.4 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares fell 11.11% to $0.35. The market value of their outstanding shares is at $15.8 million. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) shares decreased by 9.1% to $2.5. The market value of their outstanding shares is at $101.3 million. </li>
<li>Trxade Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDS#NASDAQ">MEDS</a>) shares declined by 8.82% to $16.86. The company's market cap stands at $23.7 million. </li>
<li>EUDA Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EUDA#NASDAQ">EUDA</a>) shares decreased by 8.32% to $3.42. The market value of their outstanding shares is at $120.1 million. </li>
<li>Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) stock decreased by 7.77% to $0.95. The market value of their outstanding shares is at $11.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABSI

AMIX

CNSP

DHAI

Euda Health Holdings Limited - Ordinary Shares

EUDA

GANX

MEDS

SLRX

SNTI

TRAW

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Aspira Women's Health shares are trading higher. The company announced a private placement equity financing of $1.935 million.

The company announced it has entered into a securities purchase agreement dated June 30, 2024 with certain existing accredited shareholders and Company insiders to issue and sell an aggregate of 1.264 million&nbsp;shares of its common stock&nbsp;and warrants to purchase an equal number of shares of Common Stock at a combined offering price of&nbsp;$1.53&nbsp;per share and warrant through a private placement financing.
The warrants will be exercisable for three years after date of issuance and have an exercise price of&nbsp;$2.25&nbsp;per share.
Net proceeds from the Offering will support Aspira&#39;s ongoing commercial activities as well as general corporate purposes and working capital.

Aspira Women's Health Reveals Private Placement Equity Financing Of $1.935M

Monthly OvaSuiteSM&nbsp;product volume grew by more than 26% in May compared to January &nbsp;
Reimbursement momentum continued with expanded Anthem and Medicaid coverage for OvaSuite
Cash used in operations guidance for 2024 expected to be lowered
AUSTIN, Texas, June 13, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today provided interim commercial and operational updates for the second quarter of 2024.

Aspira Women's Health Providing A Downward Revision Of The 2024 Cash Used In Operations Guidance During Q2 2024 Earnings Call

Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.34) by 14.71 percent. This is a 35 percent increase over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $2.15 million which missed the analyst consensus estimate of $2.41 million by 10.66 percent. This is a 7.04 percent decrease over sales of $2.32 million the same period last year.

Aspira Womens Health Q1 EPS $(0.39) Misses $(0.34) Estimate, Sales $2.15M Miss $2.41M Estimate

Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the publication of two peer-reviewed manuscripts. &nbsp;
The first manuscript, entitled "<a href="https://www.globenewswire.com/Tracker?data=RVFAd9d07MWxF_aCnjnkuk9rdibrdtYyZriUr87SnSBkzxNPM2_w4mosj26PRN4wHii71gNXCyMUgBKCF9v6M3fxDjrYsGb4eVh2QwEoziyLHBcTlxDTVY2a_qLbAPCTVumhzA9a7-t8dT2f-Hj3fst3cQ5w48No-jMxFfOHt_cj7jVRFC5BmbeEvl9SPf7qWbxEAf0rP_uo54crfsoCXmegQZG6CxWVdsjDY5Sy9VikAfMUACSv4t6rs_vnFzOSfr3KiIXt5AfNobtVSUah7u_cXZczJF2gOBwO08JV8to=">Ovarian Cancer Surgical Consideration is Markedly Improved by the Neural Network Powered-MIA3G Multivariate Index Assay</a>" was published in the peer-reviewed journal Frontiers of Medicine on May 2, 2024. The findings of this study demonstrate that use of OvaWatch&#xAE; to stratify risk in patients with an adnexal mass might help to reduce surgical backlogs and unnecessary surgical referrals.
The second manuscript, entitled: "<a href="https://www.globenewswire.com/Tracker?data=YhKQaHmMGxUNYNjQuaD8nUKbfzEUez7LoIZMQZcu2EwbpsBpVqZnRSwpzFfpXP-DY6O5pBZEP2eTR1rIQZ5B1lkjX2UGUlymHDtDKkITVCUth-6B-XcKDFNmseHaiTrDePsgwtK4AioZoh55Etc7vasJIam9qf7NtWpoii000pKrJXh7I_L6qa7YBwiTs-hbAkOj5DwM-xtevJ-TAlbLljasLhSLECRN7TyhatLsk5RcoB6cCgSSP_6PoHesT6Vi6BozgEctPPD0LRjTkwJUXur1Rh3QCsW0AvTMguzAhO5x57BtD21yQtjN9ycw2fbi">Neural Network-derived Multivariate Index Assay Demonstrates Effective Clinical Performance in Longitudinal Monitoring of Ovarian Cancer Risk</a>" was published in the journal Gynecologic Oncology on May 3, 2024. The findings of this study demonstrate that OvaWatch could be an effective tool for the monitoring of ovarian cancer risk over time in women with indeterminate or low risk adnexal masses. Based on common practice for adnexal mass management and consistent with the study, OvaWatch can be drawn by the provider every three to six months for active surveillance of an adnexal mass.
"Today, we mark the publication of additional clinical data to support the use of OvaWatch for the assessment of ovarian cancer risk for women with an adnexal mass," said Nicole Sandford, Chief Executive Officer of Aspira. "We believe these studies will help accelerate the adoption of OvaWatch for initial and ongoing monitoring of patients to provide an alternative to surgical intervention for lower risk cases. Clinicians have long sought a better tool to develop an appropriate care plan for these women, and OvaWatch provides it."
"The publication of these manuscripts, along with last week's announcement to make OvaWatch available for testing over time, is the latest example of Aspira keeping its promises to our stakeholders. We are well on our way to achieving our mission to improve outcomes for women with gynecologic diseases."
The total addressable market for OvaSuite, the company's portfolio of ovarian cancer risk assessment blood tests, is 2.0-3.0 million tests per year.

Aspira Women's Health Announces Publication Of Two OvaWatch Peer-Reviewed Manuscripts

Cantor Fitzgerald analyst Ross Osborn reiterates Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) with a Neutral and maintains $3.3 price target.

Reiteration

Cantor Fitzgerald Reiterates Neutral on Aspira Womens Health, Maintains $3.3 Price Target

Aspira Women's Health (AWH) just unveiled an update. Aspira Women's Health Inc. welcomes John Ragard to its Board of Directors, effective July 25, ...

Aspira Women's Health Appoints John Ragard to Board

Aspira Women's Health GAAP EPS of -$0.28 beats by $0.02, revenue of $2.4M misses by $0.2M

Aspira Women's Health Inc. (AWH) Q2 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Aspira Womens Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/awh-stock-quote/">AWH</a>) just reported results for the second quarter of 2024.<ul><li>Aspira Womens Health reported earnings per share of -28 cents. This was above the analyst estimate for EPS of -30 cents.</li><li>The company reported revenue of $2.42 million.</li><li>This was 6.81% worse than the analyst estimate for revenue of $2.60 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/awh-stock-earnings-aspira-womens-health-for-q2-of-2024/">AWH Stock Earnings: Aspira Womens Health Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

AWH Stock Earnings: Aspira Womens Health Beats EPS, Misses Revenue for Q2 2024

Aspira Women's Health ( ($AWH) ) has shared an update. Aspira Women's Health Inc. recently shared a presentation with investors, offering insights ...

Aspira Women's Health Engages Investors with Performance Insights

Cantor Fitzgerald analyst Ross Osborn maintained a Hold rating on Aspira Women's Health (AWH – Research Report) yesterday and set a price target of...

Cantor Fitzgerald Remains a Hold on Aspira Women's Health (AWH)

The Company issued the following letter to Company shareholders from CEO Nicole Sandford. "Yesterday, it was my honor to share news of an exciting ...

Aspira Women's Health issues letter to shareholders

Aspira Women's Health ( ($AWH) ) just unveiled an update. Aspira Women's Health Inc. recently showcased its product pipeline, highlighting future d...

Aspira Women's Health Highlights Future Product Developments

Aspira Women's Health reports Q3 results

Aspira Women's Health Inc. (AWH) Q3 2024 Earnings Call Transcript

Press Releases

Aspira Women's Health Partners with Dorsata to Create New Clinical Workflow Tool for Adnexal Masses

Aspira Women's Health Selected as a Spoke for the Investor Catalyst Hub

Aspira Women's Health to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aspira Women's Health Announces Publication of Data Demonstrating Performance of its In-Development Blood Test for the Assessment of Malignancy Risk in Patients with an Adnexal Mass

Aspira Women's Health Receives Approval from New York State Department of Health for OvaWatch®

Aspira Women's Health Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Aspira Women's Health Issues Letter to Shareholders and Announces Virtual Research & Development Day on October 29, 2024

Aspira Women's Health to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 14, 2024

Health Care

Aspira Women's Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch®

Comments

Aspira Womens Health

Noticias

Últimas noticias sobre Aspira Womens Health (NASDAQ:AWH) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL